Resonance Health

Resonance Health R&D Expenses

The Research & Development Expenses of Resonance Health (RHT.AX) as of Oct 16, 2026 is 433,866.00 AUD. In the previous year, Research & Development Expenses was 961,028.00 AUD — a change of -54.85% (lower).

R&D Expenses

433,866.00AUD

YoY

-54.85%

Last updated:

Research & Development Expenses of Resonance Health is 2026 433,866.00 AUD. Research & Development Expenses of Resonance Health was 2025 961,028.00 AUD. It decreases by -54.85% lower compared to the previous year.

The Resonance Health R&D Expenses history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D Expenses
Date
R&D Expenses
Jan 1, 2019
63,177.00 AUD
Jan 1, 2020
152,280.00 AUD
Jan 1, 2021
393,925.00 AUD
Jan 1, 2022
716,231.00 AUD
Jan 1, 2023
708,251.00 AUD
Jan 1, 2024
835,817.00 AUD
Jan 1, 2025
961,028.00 AUD
Jan 1, 2026
433,866.00 AUD
The Resonance Health R&D Expenses history
YEARR&D ExpensesYoY
433,866.00AUD-54.85%
961,028.00AUD+14.98%
835,817.00AUD+18.01%
708,251.00AUD-1.11%
716,231.00AUD+81.82%
393,925.00AUD+158.68%
152,280.00AUD+141.04%
63,177.00AUD-48.64%
123,016.00AUD-25.21%
164,471.00AUD+47.96%
111,157.00AUD+61.88%
68,665.00AUD-3.12%
70,874.00AUD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Resonance Health Stock analysis

What does Resonance Health do? Resonance Health Ltd is an Australian company that operates in the medical technology industry. The company's business model is to offer groundbreaking solutions for the diagnosis and treatment of liver and iron diseases. As a pioneering company in the development of methods and technologies for quantifying liver and iron concentrations, Resonance Health continually sets new standards in the industry. The company was founded in 2000 by a team of biomedicine professionals from the University of Western Australia. Over the years, the company has gained a lot of experience and constantly evolved to keep up with the progress of medical technology. The goal is to provide patients with better treatment and improved quality of life. One division of the company is the development and manufacturing of diagnostic tools for quantifying liver and iron diseases such as hepatitis, fatty liver, or hemochromatosis. The quantification method used by Resonance Health is called FerriScan. This method is non-invasive and painless, using magnetic resonance imaging (MRI) to measure the concentration of iron in the tissue. This is particularly important as a change in iron content can indicate a progressing liver disease. In addition to the FerriScan diagnostic tool, Resonance Health also offers a software package for analyzing FerriScan results, which is used by physicians and clinicians to assess disease progression. Furthermore, the company also develops solutions in the field of hemochromatosis, a genetic disorder that can lead to increased iron levels in the body. Another division of Resonance Health is the provision of research and development services to further develop and improve FerriScan and other technologies. The company collaborates with other companies, scientific institutions, and universities to advance the current developments in liver and iron diagnostics. Resonance Health has a range of products that contribute to better diagnosis and treatment of liver and iron diseases. These include FerriScan, the FerriSmart software package for precise monitoring of iron and liver health, and Hepatica, a software supporting hospitals and clinics in the diagnosis of liver diseases. The company is an innovative leader in the industry, contributing to improving the quality of life for patients. The products and services of Resonance Health have helped doctors and clinicians to effectively treat and diagnose liver and iron diseases. Additionally, the company has established a strong scientific foundation and works closely with leading institutions to continuously develop innovative solutions. Resonance Health is a company with a rich history that continues to evolve to meet the demands of the medical technology industry. The company aims to continuously improve the diagnosis and treatment of liver and iron diseases and offer better solutions. Resonance Health is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Resonance Health stock

Research & Development Expenses of Resonance Health is 433,866.00 AUD in 2026.

Research & Development Expenses of Resonance Health changed from 961,028.00 AUD to 433,866.00 AUD, representing a -54.85% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Research & Development Expenses Resonance Health since 2006 – with annual values, charts, and detailed analysis.

R&D expenses represent the costs incurred in researching and developing new products, services, or processes. High R&D spending can signal innovation and future growth potential.

Research & Development Expenses's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Research & Development Expenses's Resonance Health historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Resonance Health

All Key Metrics — Resonance Health